Article
Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance.
Journal of virology - 25 Feb 2025
Cohen Paula, Lambson Bronwen E, Mkhize Nonhlanhla N, Moodley Chivonne, Yssel Anna E J, Moyo-Gwete Thandeka, York Talita, Gwashu-Nyangiwe Asanda, Ndabambi Nonkululeko, Thebus Ruwayhida, Juraska Michal, deCamp Allan C, Williamson Brian D, Magaret Craig A, Gilbert Peter B, Westfall Dylan, Deng Wenjie, Mullins James I, Morris Lynn, Williamson Carolyn, Moore Penny L
Abstract excerpt
The Antibody Mediated Prevention (AMP) trials showed that passively infused VRC01, a broadly neutralizing antibody (bNAb) targeting the CD4 binding site (CD4bs) on the HIV-1 envelope protein (Env), protected against neutralization-sensitive viruses. We identified six individuals from the VRC01 treatment arm with multi-lineage breakthrough HIV-1 infections from HVTN703, where one variant was sensitive to VRC01...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
